Related Experiment Video
Updated: Sep 9, 2025

Integration of Brain Tissue Saturation Monitoring in Cardiopulmonary Exercise Testing in Patients with Heart Failure
Published on: October 1, 2019
Cardiopulmonary Exercise Testing for Characterization of Hypertrophic Cardiomyopathy: A Meta-Analysis
Isabela Landsteiner1, Ahmad Masri2, Sara Saberi3
1Massachusetts General Hospital Boston MA USA.
Insights
Cardiopulmonary exercise testing (CPET) offers valuable insights for hypertrophic cardiomyopathy (HCM) risk stratification. Key CPET variables effectively predict mortality, enhancing patient assessment beyond traditional methods.
Area of Science:
- Cardiology
- Exercise Physiology
- Clinical Research
Background:
- Hypertrophic cardiomyopathy (HCM) presents significant risks for adverse cardiac events.
- Accurate risk stratification and physiologic assessment are crucial for managing HCM.
- This study reviews the role of cardiopulmonary exercise testing (CPET) in HCM.
Purpose of the Study:
- To synthesize evidence on the utility of CPET for characterizing and prognosing HCM.
- To identify CPET metrics that predict outcomes in HCM patients.
Main Methods:
- Systematic search of PubMed, Embase, Scopus, and Web of Science databases up to November 2023.
- Meta-analysis of hazard ratios (HRs) and confidence intervals (CIs) for mortality.
- Inclusion of 60 articles comprising 12,914 patients with HCM.
Main Results:
- CPET revealed significant functional limitation in HCM patients (mean peak oxygen uptake: 22.4 mL/kg/min).
- CPET metrics demonstrated superior sensitivity for detecting impaired cardiac performance compared to NYHA class.
- Lower peak oxygen uptake (HR 0.86 per 1 mL/kg/min decrease) and abnormal blood pressure response (HR 2.29) predicted mortality.
Conclusions:
- CPET is an effective objective tool for assessing physiology and prognosis in HCM.
- Standardization of CPET protocols can facilitate broader clinical adoption for HCM management.
Background:
Hypertrophic cardiomyopathy (HCM) is associated with substantial risk of adverse cardiac events. Consequently, detailed physiologic assessment and accurate risk stratification in HCM are of high clinical importance. This systematic review and meta-analysis synthesizes current evidence on the utility of cardiopulmonary exercise testing (CPET) for characterization and prognostication of HCM.
Methods:
PubMed, Embase, Scopus, and Web of Science were systematically searched for eligible studies from database inception to November 2023. The primary outcome of mortality was assessed using meta-analyzed hazard ratios (HRs) and 95% confidence intervals (CIs) from Cox proportional hazard models.
Results:
Sixty full-length articles focusing on CPETs performed in patients with HCM were included, comprising 12 914 patients. Despite male predominance (66%) and a mean age of 48 years, peak oxygen uptake (pVO2) was only 22.4 mL/kg per min (95% CI, 22.3-22.5), consistent with significant functional limitation. Compared with commonly used metrics such as New York Heart Assocation functional class, CPET markedly enhances sensitivity to detect impaired cardiac performance. This meta-analysis highlights easily derived CPET variables that predict HCM prognosis. For the primary outcome, the hazard ratio per 1-mL/kg per min difference in pVO₂ was 0.86 (95% CI, 0.82-0.90; P<0.001), and the HR per 1-unit difference in minute ventilation/carbon dioxide output slope was 1.09 (95% CI, 1.05-1.13; P<0.001). Abnormal blood pressure response to exercise, defined as failure to increase systolic blood pressure by ≥20 mm Hg or a drop in systolic blood pressure >20 mm Hg, was associated with an HR of 2.29 (95% CI, 1.13-4.64; P=0.02) for mortality.
Conclusions:
CPET is a valuable objective method for multidimensional physiologic assessment and prognostication in HCM. With further standardization, CPET is well suited for more widespread clinical utilization in patients with HCM.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy IV: Restrictive Cardiomyopathy

